DreamCIS Past Earnings Performance
Past criteria checks 2/6
DreamCIS has been growing earnings at an average annual rate of 22.4%, while the Life Sciences industry saw earnings declining at 3.1% annually. Revenues have been growing at an average rate of 22% per year. DreamCIS's return on equity is 7.1%, and it has net margins of 8.8%.
Key information
22.44%
Earnings growth rate
15.28%
EPS growth rate
| Life Sciences Industry Growth | 53.72% |
| Revenue growth rate | 22.01% |
| Return on equity | 7.13% |
| Net Margin | 8.82% |
| Last Earnings Update | 31 Mar 2026 |
Recent past performance updates
DreamCIS' (KOSDAQ:223250) Performance Is Even Better Than Its Earnings Suggest
The subdued stock price reaction suggests that DreamCIS, Inc.'s ( KOSDAQ:223250 ) strong earnings didn't offer any...We Think You Should Be Aware Of Some Concerning Factors In DreamCIS' (KOSDAQ:223250) Earnings
Following the solid earnings report from DreamCIS, Inc. ( KOSDAQ:223250 ), the market responded by bidding up the stock...Recent updates
Revenue & Expenses Breakdown
How DreamCIS makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 26 | 69,872 | 6,161 | 12,318 | 720 |
| 31 Dec 25 | 66,631 | 7,126 | 11,812 | 720 |
| 30 Sep 25 | 62,064 | 18,579 | 10,992 | 920 |
| 30 Jun 25 | 63,743 | 6,414 | 11,348 | 920 |
| 31 Mar 25 | 60,892 | 5,700 | 10,747 | 920 |
| 31 Dec 24 | 58,653 | 5,280 | 10,992 | 920 |
| 30 Sep 24 | 56,883 | 4,674 | 10,994 | 733 |
| 30 Jun 24 | 53,121 | 3,820 | 10,585 | 733 |
| 31 Mar 24 | 49,771 | 3,720 | 9,917 | 733 |
| 31 Dec 23 | 47,844 | 3,739 | 9,223 | 733 |
| 30 Sep 23 | 46,491 | 2,285 | 9,366 | 440 |
| 30 Jun 23 | 42,957 | 4,108 | 8,495 | 440 |
| 31 Mar 23 | 42,657 | 4,646 | 7,667 | 440 |
| 31 Dec 22 | 38,874 | 4,405 | 6,461 | 440 |
| 30 Sep 22 | 35,778 | 5,528 | 6,048 | 277 |
| 30 Jun 22 | 31,476 | 4,229 | 5,365 | 277 |
| 31 Mar 22 | 27,133 | 2,888 | 4,584 | 277 |
| 31 Dec 21 | 26,153 | 3,229 | 4,470 | 277 |
| 30 Sep 21 | 23,234 | 2,612 | 4,306 | 316 |
| 30 Jun 21 | 22,652 | 2,875 | 4,279 | 316 |
| 31 Mar 21 | 23,498 | 4,542 | 4,322 | 316 |
| 31 Dec 20 | 23,489 | 4,854 | 4,297 | 316 |
| 30 Sep 20 | 23,051 | 4,248 | 4,267 | 141 |
| 31 Dec 19 | 22,109 | 4,151 | 3,762 | 141 |
Quality Earnings: A223250 has a large one-off gain of ₩13.9B impacting its last 12 months of financial results to 31st March, 2026.
Growing Profit Margin: A223250's current net profit margins (8.8%) are lower than last year (9.4%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: A223250's earnings have grown significantly by 22.4% per year over the past 5 years.
Accelerating Growth: A223250's earnings growth over the past year (8.1%) is below its 5-year average (22.4% per year).
Earnings vs Industry: A223250 earnings growth over the past year (8.1%) exceeded the Life Sciences industry -26.7%.
Return on Equity
High ROE: A223250's Return on Equity (7.1%) is considered low.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/07/15 17:17 |
| End of Day Share Price | 2026/07/15 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
DreamCIS, Inc. is covered by 2 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Eui-Seob Shim | NH Investment & Securities Co., Ltd. |
| Seunghwan Choi | Shinhan Investment Corp. |